Daniel R. Knight  from Murdoch University in Perth Australia.
Share

Contact me

Phone

+61 8 6457 4092

Email

Daniel.Knight@murdoch.edu.au

Fellow researchers

    Latest news

    • Research
    • School

    Dr Daniel R. Knight
    PhD UWA, BSc. Hons UCL, MASM, MASA

    NHMRC Peter Doherty Early Career Research Fellow | Riley laboratory | Medical Molecular and Forensic Sciences | College of Science, Health, Engineering and Education

    About me

    I am an NHMRC Early Career Fellow and expert in evolutionary and One Health aspects of infectious diseases epidemiology. I lead a program of research aimed at better understanding the epidemiology of Clostridium difficile Infection (CDI), one of the most important healthcare-associated infections and One Health issues in the developed world.

    I use state-of-the-art microbial genomics to study the genetic factors contributing to the emergence, evolution and spread of C. difficile in humans, animals and their shared environment. This work is at the forefront of the global efforts to better understand C. difficile evolution and challenges the long-held paradigm that CDI is exclusively a healthcare-associated infection, with implications for improved diagnostics, surveillance and treatment of CDI.

    In recognition of early career research excellence and distinguished contribution to Microbiology research in Australia, I was awarded the prestigious 2020 Jim Pittard Early Career Award by The Australian Society for Microbiology.

    • 2020 Chief Investigator funding since 2018: $526,000 AUD
    • Peer-reviewed papers: 51 (FWCI 1.74, 1250+ citations)
    • Editor, Epidemiology and Infection
    • Treasurer, Australian Society for Microbiology
    • Adjunct Postdoctoral Research Fellow, University of Western Australia

    Office and laboratory: Riley Laboratory, 2nd Floor, J Block [58.1], QEII Medical Centre, Monash Avenue, Nedlands WA 6009

    Social media: @DanRJKnight 

    Teaching area

    Murdoch University

    • Invited lecturer, Molecular epidemiology of C. difficile: BMS315 Advances in Medical Science

    The University of Western Australia

    • Invited lecturer, Antimicrobial resistance: MICR5814 Epidemiology and Infection, MICR5829 Foundations of Infectious Disease, DENT4202 Immunology, Pathology and Periodontics

     

    Research areas

    My research interest is in the field of infectious diseases molecular epidemiology and, in particular, the anaerobic bacterium Clostridium difficile. This ancient opportunistic bacterium causes disease through the production of toxins that affect the gut. C. difficile infection (CDI) can lead to life-threatening diarrhoea in humans and livestock, particularly piglets. In the last decade CDI has reached an epidemic state with increasing incidence and severity in both healthcare and community settings. C. difficile is also an important antimicrobial resistant (AMR) pathogen, currently ranked by the US Centers for Disease Control and Prevention as the number one AMR threat to public health in the USA.

    My PhD research has shown that livestock in Australia are reservoirs for important strains of C. difficile. For the first time, inter-species transmission of C. difficile between livestock and humans was demonstrated. These findings provide compelling evidence that CDI has a foodborne or zoonotic aetiology, and challenge the existing paradigm and long-held misconception that CDI is primarily a healthcare-associated infection.

    Through the application of state-of-the-art microbial genomics, the goal of my research is to provide insights into the factors contributing to the emergence, evolution and spread of C. difficile. This will lead to a better understanding of the zoonotic potential of this important pathogen, and its contribution to antimicrobial resistance. These outcomes will be essential for the development of a “One Health” approach to control strategies to reduce the impact of CDI in humans and animals and safeguard Australia’s biosecurity.

    Current projects

    NHMRC Early Career Research Fellowship, 2018-2021 (VLS, Murdoch)

    A One Health approach to assessing the threat of Clostridium difficile to Australia’s biosecurity: a genomic investigation of human, animal and environmental isolates. Key skills: Bioinformatics, comparative genomics, bacterial genetics, CRISPR typing and Bayesian modelling

     

    Awards and grants

    Competitive grants

    • Knight DR. Raine Priming Grant, 2019-2020. ‘One Health: A new paradigm for studying evolution and transmission in Clostridium difficile’. Raine Medical Research Foundation, (RPG002-19), $199,950.
    • Knight, DR. Peter Doherty Early Career Biomedical Research Fellowship, 2018-2021. “A One Health approach to assessing the threat of Clostridium difficile to Australia’s biosecurity: a genomic investigation of human, animal and environmental isolates”. National Health and Medical Research Council, (APP1138257), $327,193.

    Major awards

    • Knight, DR. 2020 recipient of the 2020 ASM Jim Pittard Early Career Award (Australian Society for Microbiology) in recognition of early career research excellence and distinguished contribution to Australian research in Microbiology.
    • Knight, DR. 2020 recipient of the 2021 Raine Research Prize (Raine Medical Research Foundation) for the best scientific paper by a WA Early Career Researcher in medical science.

    Other awards, prizes and scholarships

    • Knight, DR. 2018 International One Health Fellowship, The One Health Platform. June 2018, Saskatoon, Canada ($3,600).
    • Knight, DR. Travel Award, 19th Annual Scientific Meeting of the Australian Society for Antimicrobials (ASA). Feb 2018, Brisbane, Queensland, Australia. ($2,500).
    • Knight, DR. Best ‘One Health’ Presentation, 10th International Conference on the Molecular Biology and Pathogenesis of the Clostridia (CLOSTPATH). Aug 2017, Ann Arbor, Michigan, USA. (Book Prize).
    • Knight, DR. Trainee Travel Award, 10th International Conference on the Molecular Biology and Pathogenesis of the Clostridia (CLOSTPATH). Aug 2017, Ann Arbor, Michigan, USA ($815).
    • Knight, DR. ASM Nancy Millis Student Award, Australian Society for Microbiology (ASM), July 2016 ($470).
    • Knight, DR. Wellcome Trust Advanced Courses Scholarship and Postgraduate Travel Award, April 2015. Wellcome Trust, European Bioinformatics Institute and The University of Western Australia. ($3,170).
    • Knight, DR. Australian Postgraduate Award, 2013-2017. Australian Federal Government. ($86,000).
    • Knight, DR. Postgraduate Scholarship, 2013-2017. The University of Western Australia. ($63,000).

    Events and speaking engagements

    Invited talks at national and international scientific meetings

    • Jul 2020. Invited symposium speaker, 15th Biennial Congress of the Anaerobe Society of the Americas. Seattle, USA. Title: Genomic and Evolutionary Insights into C. difficile, the Quintessential One Health Pathogen.
    • Apr 2019. Invited symposium speaker, 29th Annual Congress of the European Society of Clinical Microbiology and Infectious Diseases (ECCMID). Amsterdam, Netherlands. Title: New evidence for a zoonotic potential of Clostridium difficile.
    • Sept 2018. Invited symposium speaker, 6th International Clostridium difficile Symposium. Bled, Slovenia. Title: One Health: the optimal paradigm for studying evolution and transmission in C. difficile
    • July 2018. Invited symposium speaker, 46th Annual Scientific Meeting Australian Society Microbiology. Brisbane, Australia. Title: Clostridium difficile Infection in Australia: not so nosocomial anymore.
    • Feb 2018. Proffered paper selected from abstracts, 19th Annual Scientific Meeting Australian Society for Antimicrobials. Brisbane, Australia. Title: AMR in zoonotic lineages of C. difficile.
    • July 2016. Award plenary session, proffered paper selected from abstracts, 44th Annual Scientific Meeting Australian Society Microbiology. Perth, Australia. Title: Microevolutionary analysis of C. difficile PCR ribotype 014 lineage in Australian porcine and humans reveals signatures of long-range intra- and interspecies transmission.
    • Feb 2016. Proffered paper selected from abstracts, 17th Annual Scientific Meeting Australian Society for Antimicrobials. Melbourne, Australia. Title: Intrinsic and acquired antimicrobial resistance repertoire of Australian isolates of C. difficile identified on WGS.
    • Nov 2012. Proffered paper selected from abstracts, 4th Biannual Conference of the Australian Pig Science Association. Melbourne, Australia. Title: Prevalence and molecular characterisation of C. difficile in neonatal piglets in Australia.
    • Sept 2012. Proffered paper selected from abstracts, 4th International Clostridium difficile Symposium (ICDS). Bled, Slovenia. Title: C. difficile from Australian cattle – all will be revealed!

    Invited talks at local scientific meetings

    • November 2019. Invited speaker, One Health: the optimal paradigm for studying evolution and transmission in Clostridium difficile. Infectious Diseases Breakfast Seminar Series, The University of Western Australia, PathWest Laboratory Medicine, Perth, Western Australia, Australia.
    • May 2019. Invited symposium speaker, Pathogen Discovery: From Genomics to Disease Recognition and Response. Two-day symposium co-hosted by PathWest Laboratory Medicine WA, the University of Western Australia, the NHMRC Centre of Research Excellence in Emerging Infectious Diseases (CREID) and the NHMRC Australian Partnership for Preparedness Research on Infectious Disease Emergencies (APPRISE). Perkins Institute for Medical Research, QEII medical centre, Perth, Western Australia, Australia. Title: Clostridium difficile infection: new insights in to AMR and zoonotic transmission.
    • Apr 2018. Invited symposium speaker, COMBINE Network Seminar Event, The Australian Bioinformatics And Computational Biology Society (ABACBS). Perkins Institute for Medical Research, QEII medical centre, Perth, Western Australia, Australia. Title: Using microbial genomics to provide novel insights into Clostridium difficile Infection.
    • Aug 2017. Invited symposium speaker, The Marshall Centre for Infectious Diseases Research and Training Seminar series 2017. The University of Western Australia, Perth, Western Australia. Title: Clostridium difficile ‒ the quintessential One Health pathogen.
    • Dec 2016. Invited symposium speaker, West Coast Microbiome Network (WCMN) Seminar Series 2016. Curtin University, Curtin, Western Australia. Title: Genomic signatures of interspecies transmission in the enteric pathogen Clostridium difficile.
    • Oct 2016. Invited symposium speaker, The University of Western Australia and PathWest Laboratory Medicine Research Day 2016. The University of Western Australia, Perth, Western Australia. Title: Evolutionary analysis of C. difficile ribotype 014 lineage in Australian pigs and humans.

    Professional and community service

    Editorial Activities

    • Editor, Epidemiology and Infection (2019-)

    Peer Review Activities (Invited)

    • Journal of Clinical Microbiology
    • Journal of Global Antimicrobial Resistance
    • Antimicrobial Agents and Chemotherapy
    • BMC Infectious Diseases
    • Letters in Applied Microbiology
    • Clinical Microbiology Reviews
    • Microbial Genomics
    • Foodborne Pathogens and Disease
    • Anaerobe
    • Zoonoses and Public Health

    Australian Society for Microbiology (ASM)

    • Member (MASM) since 2012
    • Committee member (WA branch) since 2013.
      • Current role: Treasurer (2019-)
      • Previous roles: Communications (2013-16), Awards and scholarships (2017-18), Scientific program (2018-19)

    Local Organising Committees (LOCs)

    • Secretary, ASM national scientific meeting 2016 (Perth, WA)
    • Founding member and scientific program convener, West Coast Microbiome Network (WCMN) symposiums 2016, 2017, 2018. 2019, 2020 (Perth, WA)
    • BacPath 15, The Molecular Biology of Bacterial Pathogens 2019 (Perth, WA)

    Other membership

    • Australian Society for Antimicrobials (ASA)
    • International Society for Infectious Diseases (ISID)
    • Society for Anaerobic Microbiology (SAM)
    • Early/Mid-Career Researcher Forum, Australian Academy of Science (EMCR)

    National Health and Medical Research Council (NHMRC)

    • ECR Review Panel Observer (Project Grants 2018)
    • Peer Review Panel Member (Investigator Grants 2019)

    Doctoral and masters supervisions

    Ms Stacey Hong; PhD (2014-2020, submitted Oct 2020), University of Western Australia.

    • Molecular epidemiology of emerging C. difficile RT251 in Australia.

    Dr Korakrit Imwattana; PhD (2019-), University of Western Australia.

    • Phylogenetics and clinical epidemiology of global epidemic C. difficile RT017.

    Ms Karla Cautivo; PhD (2019-), Murdoch University.

    • Evolution of C. difficile in native fauna and soils in Western Australia.

    Ms Natasza Hain-Saunders; PhD (2020-), Murdoch University.

    • Molecular epidemiology of Clostridium difficile Infection in equine populations in Australia.

    Ms Keeley O’Grady; MSc (2019-), Murdoch University.

    • Epigenetic control of antimicrobial resistance in C. difficile.

    Publications

    REFEREED JOURNAL ARTICLES

    2020

    • Hong S, Putsathit P, George N, Hemphill C, Huntington PG, Korman TM, Kotsanas D, Lahra M, McDougall R, Moore C, Nimmo G, Prendergast L, Robson J, Waring L, Wehrhahn MC, Weldhagen GF, Wilson R, Riley TV, Knight DR. Laboratory-based surveillance of Clostridium difficile infection in Australian healthcare and community settings, 2013–2018. J Clin Microbiol 58 (11) e01552-20 https://doi.org/10.1128/JCM.01552-20
    • Imwattana K, Kiratisin P, Riley TV, Knight DR. 2020. Genomic basis of antimicrobial resistance in non-toxigenic Clostridium difficile in Southeast Asia. Anaerobe. [In Press, Nov 2020]. https://doi.org/10.1016/j.anaerobe.2020.102290
    • Lim S‐C., Knight DR, Moono P, Foster NF, Riley TV. 2020. Clostridium difficile in soil conditioners, mulches and garden mixes with evidence of a clonal relationship with historical food and clinical isolates. Environ Microbiol Rep. [In Press, Oct 2020]. https://doi.org/10.1111/1758-2229.12889
    • Lim S-C , Riley TV, Knight DR. 2020. One Health: the global challenge of Clostridium difficile infection. Microbiol Aust 41:23-27. https://doi.org/10.1071/MA20007
    • Imwattana K, Knight DR, Kullin B, Collins DA, Putsathit P, Kiratisin P, Riley TV. 2019. Antimicrobial resistance in Clostridium difficile ribotype 017. Expert Rev Anti Infect Ther 18:17-25. https://doi.org/10.1080/14787210.2020.1701436

    2019

    • Lim S-C, Knight DR, Riley TV. 2019. Clostridium difficile and One Health. Clin Microbiol Infect S1198-743X(19)30559-2. https://doi.org/10.1016/j.cmi.2019.10.023
    • Putsathit P, Neela VK, Joseph NMS, Oiu PT, Ngamwongsatit B, Knight DR, Riley TV. 2019. Molecular epidemiology of Clostridium difficile isolated from piglets. Vet Microbiol 237:108408. https://doi.org/10.1016/j.vetmic.2019.108408
    • Androga GO, Knight DR, Hutton ML, Mileto SJ, James ML, Evans C, LyrasD, Chang BJ, Foster NF, Riley TV. 2019. In silico, in vitro and in vivo analysis of putative virulence factors identified in large clostridial toxin-negative, binary toxin-producing C. difficile strains. Anaerobe 60:102083. https://doi.org/10.1016/j.anaerobe.2019.102083
    • Hong S, Knight DR, Chang B, Carman RJ, Riley TV. 2019. Phenotypic characterisation of Clostridium difficile PCR ribotype 251, an emerging multi-locus sequence type clade 2 strain in Australia. Anaerobe 60:102066. https://doi.org/10.1016/j.anaerobe.2019.06.019
    • Knight DR, Riley TV. 2019. Genomic delineation of zoonotic origins of Clostridium difficile. Front Public Health 7:164. https://doi.org/10.3389/fpubh.2019.00164
    • Imwattana K, Knight DR, Kullin B, Collins DA, Putsathit P, Kiratisin P, Riley TV. 2019. Clostridium difficile ribotype 017 – characterization, evolution and epidemiology of the dominant strain in Asia. Emerg Microbes Infect, 8:796-807. https://doi.org/10.1080/22221751.2019.1621670
    • Azimirad M, Gholami F, Yadegar A, Knight DR, Shamloei S, Aghdaei HA, Zali MR. 2019. Prevalence and characterization of Clostridium perfringens toxinotypes among patients with antibiotic-associated diarrhea in Iran. Sci Rep 9:7792. https://doi.org/10.1038/s41598-019-44281-5
    • Knight DR, Kullin B, Androga GO, Barbut F, Eckert C, Johnson S, Spigaglia P, Tateda K, Tsai PJ, Riley TV. 2019. Evolutionary and genomic insights into Clostridioides difficile sequence type 11: a diverse, zoonotic and antimicrobial resistant lineage of global One Health importance. mBio 10:e00446-19. https://doi.org/10.1128/mBio.00446-19
    • Hong S, Knight DR, Riley TV. 2019. The impact of antimicrobial resistance on induction, transmission and treatment of Clostridium difficile infection. Microbiol Aust 40:77-81. https://doi.org/10.1071/MA19022
    • Tague AJ, Putsathit P, Hutton ML, Hammer KA, Wales SM, Knight DR, Riley TV, Lyras D, Keller PA, Pyne SG. 2019. Cationic biaryl 1,2,3-triazolyl peptidomimetic amphiphiles targeting Clostridioides (Clostridium) difficile: synthesis, antibacterial evaluation and an in vivo C. difficile infection model. Eur J Med Chem 170:203-224. https://doi.org/10.1016/j.ejmech.2019.02.068
    • Tague AJ, Putsathit P, Hammer KA, Wales SM, Knight DR, Riley TV, Keller PA, Pyne SG. 2019. Cationic biaryl 1,2,3-triazolyl peptidomimetic amphiphiles: Synthesis, antibacterial evaluation and preliminary mechanism of action studies. Eur J Med Chem 168:386-404. https://doi.org/10.1016/j.ejmech.2019.02.013
    • Wehrhahn MC, Keighley C, Kurtovic J, Knight DR, Hong S, Hutton M, Lyras D, Wang Q, Leong R, Borody T, Edye M, Riley TV. 2019. A series of three cases of severe Clostridium difficile infection in Australia associated with a binary toxin producing clade 2 ribotype 251 strain. Anaerobe 55:117-123. https://doi.org/10.1016/j.anaerobe.2018.11.009
    • Roshan N, Riley TV, Knight DR, Steer JH, Hammer KA. 2019. Natural products show diverse mechanisms of action against C. difficile. J Appl Microbiol 126:468-479. https://doi.org/10.1111/jam.14152
      2018
    • Roshan N, Riley TV, Knight DR, Hammer KA. 2018. Effect of natural products on the production and activity of Clostridium difficile toxins in vitro. Sci Rep 8:15735. https://doi.org/10.1038/s41598-018-33954-2
    • Androga GO, Knight DR, Lim SC, Foster NF, Riley TV. 2018. Antimicrobial resistance in large clostridial toxin-negative, binary toxin-positive Clostridium difficile ribotypes. Anaerobe 54:55-60. Authors contributed equally to this work. https://doi.org/10.1016/j.anaerobe.2018.07.007
    • Lim S-C, Androga GO, Knight DR, Moono P, Foster NF, Riley TV. 2018. Antimicrobial susceptibility of Clostridium difficile isolated from food and environmental sources in Western Australia. Int J Antimicrob Agents 52: 411-415. https://doi.org/10.1016/j.ijantimicag.2018.05.013
    • Amy J, Bulach D, Knight DR, Riley TV, Johanesen P, Lyras D. 2018. Identification of large cryptic plasmids in Clostridioides (Clostridium) difficile. Plasmid 96-97:25-38. http://dx.doi.org/10.1016/j.plasmid.2018.04.001
    • Man NYT,  Knight DR, Stewart SG, McKinley AJ, Riley TV, Hammer KA. 2018. Spectrum of antibacterial activity and mode of action of a novel tris-stilbene bacteriostatic compound. Sci Rep 8:6912. http://dx.doi.org/10.1038/s41598-018-25080-w

    2017

    • McGovern AM, Androga GO, Knight DR, Watson MW, Elliott B, Foster NF, Chang BJ, Riley TV. Prevalence of binary toxin positive Clostridium difficile in diarrhoeal humans in the absence of epidemic ribotype 027. PLoS One 12:e0187658. http://dx.doi.org/10.1371/journal.pone.0187658
    • PutsathitP, Maneerattanaporn M, PiewngamP, Knight DR, Kiratisin P, Riley TV. Antimicrobial susceptibility of Clostridium difficile isolated in Thailand. Antimicrob Resist Infect Con 6:58. http://dx.doi.org/10.1186/s13756-017-0214-z
    • Knight DR, Squire MM, Collins DA, Riley TV. Genome analysis of Clostridium difficile PCR ribotype 014 lineage in Australian pigs and humans reveals a diverse genetic repertoire and signatures of long-range interspecies transmission. Front Microbiol 7:2138. http://dx.doi.org/10.3389/fmicb.2016.02138
    • Elliott B, Androga GA, Knight DR, Riley TV. Clostridium difficile infection: evolution, phylogeny and molecular epidemiology. Infect Genet Evol 49:1-11. http://dx.doi.org/10.1016/j.meegid.2016.12.018

    2016

    • Moono P, Foster NF, Hampson DJ, Knight DR, Bloomfield LE, Riley TV. Clostridium difficile Infection in Production Animals and Avian Species: A Review. Foodborne Pathog Dis 13:647-655. http://dx.doi.org/10.1089/fpd.2016.2181
    • McGovern AM, Foster NF, Pereira AL, Knight DR, Elliott B, Chang BJ, Riley TV. Human Clostridium difficileinfection caused by a livestock-associated PCR ribotype 237 strain in Western Australia. J Med Microbiol Case Rep 3. http://dx.doi.org/10.1099/jmmcr.0.005062
    • Knight DR, Androga GA, Ballard SA, Howden BP, Riley TV. A phenotypically silent vanB2 operon carried on a Tn1549-like element in Clostridium difficile. mSphere 1: e00177-16. http://dx.doi.org/10.1128/mSphere.00177-16
    • Knight DR and Riley TV. Clostridium difficile clade 5 in Australia: antimicrobial susceptibility profiling of PCR ribotypes of human and animal origin. J Antimicrob Chemother 71: 2213-2217. http://dx.doi.org/10.1093/jac/dkw124
    • Knight DR, Putsathit P, Elliott B, Riley TV. Contamination of Australian newborn calf carcasses at slaughter with Clostridium difficile. Clin Microbiol Infect 22: 266.e1–266.e7. http://dx.doi.org/10.1016/j.cmi.2015.11.017

    2015

    • Moono P, Putsathit P, Knight DR, Squire MM, Hampson DJ, Foster NF, Riley TV. Persistence of Clostridium difficile RT 237 infection in a Western Australian piggery. Anaerobe 37: 62-66. http://dx.doi.org/10.1016/j.anaerobe.2015.11.012
    • Squire MM, Knight DR, Riley TV. Community-acquired Clostridium difficile infection and Australian food animals. Microbiol Aust 36(3). http://dx.doi.org/10.1071/MA15040
    • Knight DR, Giglio S, Huntington PG, Korman TM, Kotsanas D, Moore CV, Paterson DL, Prendergast L, Huber CA, Robson J, Waring L, Wehrhahn MC, Weldhagen GF, Wilson RM, Riley TV. Surveillance for antimicrobial resistance in Australian isolates of Clostridium difficile, 2013-2014. J Antimicrob Chemother 70: 2992-9. http://dx.doi.org/10.1093/jac/dkv220
    • Knight DR, Hart J, Gottardo NG, Eyre DW, Crook DW, Riley TV. Two cases of Clostridium difficile infection in unrelated oncology patients attributable to a single clone of C. difficile PCR ribotype 126. J Med Microbiol Case Rep 2. http://dx.doi.org/10.1099/jmmcr.0.000043
    • Knight DR, Elliott B, Chang B, Perkins TT, Riley TV. Diversity and evolution in the genome of Clostridium difficile. Clin Microbiol Rev 28: 721-741. http://dx.doi.org/10.1128/CMR.00127-14
    • Grandgirard D, Furi L, Ciusa ML, Baldassarri L, Knight DR, Morrissey I, Largiadèr CR, Leib SL, Oggioni MR. Mutations upstream of fabI in triclosan-resistant Staphylococcus aureus strains are associated with elevated fabI gene expression. BMC Genomics 16:345. http://dx.doi.org/10.1186/s12864-015-1544-y
    • Oggioni MR, Coelho JR, Furi L, Knight DR, Viti C, Orefici G, Martinez JL, Freitas AT, Coque T, Morrissey I. Significant differences characterize the correlation coefficients between biocide and antibiotic susceptibility profiles in Staphylococcus aureus. Curr Pharm Des 21: 2054-7. http://dx.doi.org/10.2174/1381612821666150310103238

    2014

    • Knight DR, Squire MM, Riley TV. Nationwide surveillance study of Clostridium difficile in Australian neonatal pigs shows high prevalence and heterogeneity of PCR ribotypes. Appl Environ Microbiol 81: 119-123. http://dx.doi.org/10.1128/AEM.03032-14
    • Knight DR, Squire MM, Riley TV. Laboratory detection of Clostridium difficile in piglets in Australia. J Clin Microbiol 52: 3856-62. http://dx.doi.org/10.1128/JCM.01225-14
    • Hart J, Putsathit P, Knight DR, Sammels L, Riley TV, Keil A. Clostridium difficile infection diagnosis in a paediatric population: comparison of methodologies. Eur J Clin Microbiol Infect Dis 33: 1555-64. http://dx.doi.org/10.1007/s10096-014-2108-9
    • Morrissey I, Oggioni MR, Knight DR, Curiao T, Coque T, Kalkanci A, Martinez JL. 2014. Evaluation of epidemiological cut-off values indicates that biocide resistant subpopulations are uncommon in natural isolates of clinically-relevant microorganisms. PLoS One 9: e86669. http://dx.doi.org/10.1371/journal.pone.0086669

    2013

    • Friedman ND, Pollard J, Stuart D, Alfredson D, Knight DR, Davey E, Parry L, Riley TV. Prevalence of Clostridium difficile colonization among healthcare workers. BMC Infect Dis 13:459. http://dx.doi.org/10.1186/1471-2334-13-459
    • Knight DR and Riley TV. Prevalence of Clostridium difficile gastrointestinal carriage in Australian sheep and lambs. Appl Environ Microbiol 79:5689-92. http://dx.doi.org/10.1128/AEM.01888-13
    • Furi L, Ciusa ML, Knight DR, Di Lorenzo V, Tocci N, Cirasola D, Aragones L, Coelho JR, Freitas AT, Marchi E, Moce L, Visa P, Northwood JB, Viti C, Borghi E, Orefici G, Morrissey I, Oggioni MR. Evaluation of reduced susceptibility to quaternary ammonium compounds & bisbiguanides in clinical isolates and laboratory-generated mutants of Staphylococcus aureus. Antimicrob Agents Chemother 57:3488-3497. http://dx.doi.org/10.1128/AAC.00498-13
    • Knight DR, Thean S, Putsathit P, Fenwick S, Riley TV. Cross-sectional study reveals high prevalence of C. difficile non-PCR ribotype 078 strains in Australian veal calves at slaughter. Appl Environ Microbiol 79:2630-5. http://dx.doi.org/10.1128/AEM.03951-12

    2012

    • Morrissey I, Seifert H, Canton R, Nordmann P, Stefani S, MacGowan A, Janes R, Knight DR. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci, and b-haemolytic streptococci collected from western European countries in 2011. J Antimicrob Chemother 68:164-167. http://dx.doi.org/10.1093/jac/dks344
    • Cuisa ML, Furi L, Knight DR, Decorosi F, Fondi M, Raggi C, Coelho JR, Aragones L, Moce L, Visa P, Freitas AT, Baldassarri L, Renato F, Viti C, Orefici G, Martinez JL, Morrissey I, Oggioni MR. A novel resistance mechanism to triclosan witnesses horizontal gene transfer and demonstrates selective pressure for reduced biocide susceptibility in clinical strains of S. aureus. Int J Antimicrob Agents 40:210-220.Authors contributed equally to this work. http://dx.doi.org/10.1016/j.ijantimicag.2012.04.021
    • Coelho JR, Carriço JA, Knight DR, Martinez J, Morrissey I, Oggioni MR, Freitas AT. The use of machine learning methodologies to analyze antibiotic and biocide susceptibility in S. aureus. PLoS One 8:e55582. http://dx.doi.org/10.1371/journal.pone.0055582

    2005

    • Huber PA, Birdsey GM, Lumb MJ, Prowse DT, Perkins TJ, Knight DR and Danpure CJ. Peroxisomal import of human alanine: glyoxylate aminotransferase (AGT) requires ancillary targeting information remote from its C-terminus. J Biol Chem 280:27111-20. http://dx.doi.org/10.1074/jbc.M502719200

    MEDIA

    PREPRINT ARTICLES (UNPUBLISHED)

    Knight DR, Imwattana K, Kullin B, Guerrero-Araya E, Paredes-Sabja D, Didelot X, Dingle KE, Eyre DW, Rodríguez C, and Riley TV. The Clostridioides difficile species problem: global phylogenomic analysis uncovers three ancient, toxigenic, genomospecies. bioRxiv 2020.09.21.307223 https://doi.org/10.1101/2020.09.21.307223

    CONFERENCE PROCEEDINGS – 48 peer-reviewed poster and oral abstracts, 13 as first or senior author, all available at Figshare.